Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib
André Fuchs, Hans-Martin Orth, Ulrich Germing, Mustafa Kondakci, Martha Holtfreter, Torsten Feldt, Björn‐Erik Ole Jensen, Dieter Häussinger
Abstract
JAK/STAT signaling plays a major role in the pathogenesis of secondary hemophagocytic lymphohistiocytosis. This case report on a critically ill patient with secondary hemophagocytic lymphohistiocytosis due to falciparum malaria treated successfully with ruxolitinib, demonstrates that JAK1/2 inhibition might be a promising treatment option for severe cases.
Topics & Concepts
Hemophagocytic lymphohistiocytosisRuxolitinibMedicineMalariaImmunologyInternal medicineMyelofibrosisBone marrowDiseaseAutoimmune and Inflammatory Disorders ResearchImmune Cell Function and InteractionParvovirus B19 Infection Studies